***What is already known about this topic?*** The coronavirus disease 2019 pandemic caused dramatic changes to daily routines and health care delivery in the United States.***What does this article add to our knowledge?*** Coronavirus disease 2019 public health interventions were accompanied by a reduction in pediatric asthma encounters and systemic steroid prescriptions. Decreased rhinovirus infections may have contributed to this apparent reduction in asthma exacerbations, although changes in 4 criteria air pollutants were not significantly different than historical trends.***How does this study impact current management guidelines?*** Our findings reinforce the value of preventative measures for asthma control, especially those designed to limit transmission of respiratory viruses.

Introduction {#sec1}
============

Coronavirus disease 2019 (COVID-19), an illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), arose in late 2019 and rapidly spread around the world. By June 2020, more than 9 million cases and 469,000 deaths had been reported worldwide, with 2.3 million cases and 122,000 deaths in the United States.[@bib1] In response to COVID-19,[@bib2] health care systems reoriented their delivery structures to prepare for a dramatic increase in COVID-19 cases while attempting to shield unaffected individuals from infection. Simultaneously, various local and national public health interventions designed to limit viral transmission were enacted. At Children\'s Hospital of Philadelphia (CHOP), the first COVID-19 patient tested positive for SARS-CoV-2 on March 17, 2020. On this date, all nonessential businesses in Philadelphia were prohibited from operating in person.[@bib3] Subsequently, the city enacted a stay-at-home order and a closure of schools, with the intent to limit physical interactions among people and prevent transmission of the virus. Concern arose among patients and their parents that visiting a hospital or doctor\'s office put them at increased risk for contracting COVID-19, resulting in deferral of many in-person well-child and routine follow-up care visits.[@bib4] ^,^ [@bib5] For all these reasons, many health care systems, including CHOP, adopted video telemedicine (VTM).[@bib6]

Asthma is one of the most common chronic childhood diseases, affecting 1 of 12 school-age children in the United States,[@bib7] with a higher prevalence in Philadelphia than the national mean.[@bib8] ^,^ [@bib9] Pollution and respiratory virus exposure, in particular rhinovirus (RV),[@bib10] ^,^ [@bib11] can worsen asthma symptoms and trigger exacerbations.[@bib12] For example, exposure to US Environmental Protection Agency (EPA) criteria air pollutants, including particulate matter less than 2.5 microns (PM~2.5~), particulate matter less than 10 microns (PM~10~), ozone, and nitrogen dioxide (NO~2~), has been associated with increased asthma exacerbations[@bib13], [@bib14], [@bib15], [@bib16] and increased risk of developing asthma.[@bib17] Viral respiratory infections are also associated with most pediatric asthma exacerbations,[@bib18] and people with asthma experience more severe, longer-lasting respiratory viral infections than people without asthma.[@bib19] Based on these findings, it was thought that people with asthma were at risk for worse COVID-19 outcomes,[@bib20] ^,^ [@bib21] although subsequent observational studies have found mixed results in support of this hypothesis.[@bib22], [@bib23], [@bib24]

The public health interventions adopted to slow down the transmission of SARS-CoV-2 have altered environmental exposure profiles, which also influence the risk of asthma exacerbations. Infection prevention measures, including wearing face masks, washing hands frequently, and social distancing as a result of stay-at-home orders and school closures, reduce person-to-person transmission of all respiratory viruses. The decrease in transportation and industrial activity resulting from COVID-19 restrictions has reduced the emission of primary air pollutants worldwide,[@bib25] ^,^ [@bib26] and there is current interest in determining the extent to which these changes have affected asthma symptoms.[@bib27] In this study, we sought to describe the impact of COVID-19 public health measures on pediatric asthma-related health care utilization, respiratory virus testing in our emergency department (ED), and pollution levels in the greater Philadelphia area.

Methods {#sec2}
=======

Study population {#sec2.1}
----------------

We extracted asthma patient encounter data corresponding to the time period January 17 to May 17 for the years 2015 to 2020 from the CHOP Care Network, which consists of 48 outpatient primary and specialty care clinical sites, 4 urgent care sites, 15 community hospital alliances, and a 557-bed quaternary care center in the greater Philadelphia area. Data from this network have previously been validated as a tool to assess regional disease trends.[@bib8] ^,^ [@bib28] Asthma diagnosis was established on the basis of encounters having an *International Classification of Diseases, Tenth Revision* code J45.nn. Accuracy of this definition was confirmed via manual review of 100 patient charts.

Variable selection {#sec2.2}
------------------

For each encounter, its type (ie, inpatient, ED, outpatient, telephone, and VTM) and date were extracted, along with data on the patient\'s sex, race, ethnicity, date of birth, and payer type. Race was based on self- or parent/guardian selection of 1 of the following categories: "white," "black," "Asian or Pacific Islander," or "Other." Subjects without a race selection were coded as "Unknown." Codified asthma-related drug prescription data for all outpatient asthma-related prescriptions, and for outpatient and inpatient systemic steroid prescriptions, were obtained from CHOP provider prescription records (see [Table E1](#tblE1){ref-type="table"} in this article\'s Online Repository at [www.jaci-inpractice.org](http://www.jaci-inpractice.org){#intref0010}).

Virology data {#sec2.3}
-------------

CHOP ED results for respiratory viral testing for adenovirus, influenza A virus (IFV-A), influenza B virus (IFV-B), parainfluenza 1, parainfluenza 2, parainfluenza 3, non--COVID-19 coronavirus, metapneumovirus, respiratory syncytial virus (RSV), RV, and COVID-19 via PCR testing were extracted from CHOP\'s Respiratory Virus Prevalence database. Data for the number of positive test results and tests administered for each virus for the time period January 17 to May 17 during the years 2015 to 2020 were obtained. The number of positive test results for each virus was compared with (1) the total number of tests administered for that virus only and (2) the overall number of viral tests administered for all the viruses listed above.

Air pollution data {#sec2.4}
------------------

Hourly PM~2.5,~ PM~10~, ozone, and NO~2~ measures obtained at EPA monitoring sites in Philadelphia for the time period January 17 to May 17 during the years 2015 to 2020 were extracted from AirNow, an air quality data management system that reports real-time and forecast air quality estimates.[@bib29] Because historical data were not available for all pollutants in AirNow, we also downloaded daily summary files for the time period January 17 to May 17 during the years 2015 to 2019 from Air Data, an EPA resource that provides quality-assured summary air pollution measures collected from outdoor regulatory monitors across the United States.[@bib30] In Philadelphia, the same monitoring sites transmitted data to AirNow and AirData.

Data analysis {#sec2.5}
-------------

Characteristics of encounters, viral test results, and pollutant levels from the 60-day period before and after March 17, 2020 were compared with those from the period 2015 to 2019. A paired Student *t* test was used to examine differences in systemic steroid prescription rates between patients before and after March 17. For both viral testing and pollution data, controlled interrupted time series regression models were created to identify statistically significant changes between the pre--and post--March 17 60-day time frames that differed in 2020 compared with the 2015 to 2019 historical time period. Significant differences between 2020 and historical data were determined on the basis of *P* values for regression coefficients corresponding to interaction terms of variables representing pre--and post--March 17 status, the year(s) in question, and/or days. For viral testing, 2-way ANOVA and mixed-effect analysis were additionally used to test for significant differences. To visualize pollution levels across Philadelphia during time periods of interest, we generated 100 m × 100 m grid raster layers using inverse-distance-squared weighted averaging of pollutant measures from the 5 nearest monitoring stations. Analyses were performed in GraphPad Prism (GraphPad Software, San Diego, Calif) and R (R Foundation, Vienna, Austria).[@bib31] Results were summarized as percentage change.

Data availability {#sec2.6}
-----------------

The epidemiologic data sets supporting the conclusions of this article are available in the Zenodo repository (<https://zenodo.org/record/3981568>).

Ethical and regulatory oversight {#sec2.7}
--------------------------------

The CHOP Institutional Review Board reviewed our study and determined it did not meet the definition of Human Subjects research.

Results {#sec3}
=======

Asthma health care utilization decreased and VTM encounters increased after COVID-19 public health interventions {#sec3.1}
----------------------------------------------------------------------------------------------------------------

Before the public health measures enacted on March 17, 2020 in Philadelphia to limit COVID-19 spread, asthma health care visit numbers and encounter types at CHOP were similar to historical averages for the period 2015 to 2019. Overall, there was a 60% decrease in total daily asthma health care visits at CHOP when comparing the 60 days before and after March 17, 2020 (102.44 ± 48.9; range, 19-190, and 41.5 ± 25.7, range, 0-94, respectively) ([Figure 1](#fig1){ref-type="fig"} ). Before March 17, 2020, the average numbers of outpatient and hospital (ED + inpatient) daily asthma encounters were 72.5 ± 46.2 (range, 0-154) and 25.7 ± 6.6 (range, 0-41), respectively. After March 17, 2020, the average number of daily outpatient encounters decreased by 87% to 9.2 ± 8.2 (range, 0-44), while hospital encounters decreased by 84% to 4.2 ± 3.8 (range, 0-18). Concurrently, asthma telephone encounters across the network increased by 19% from a daily average of 4.3 ± 4.2 (range, 0-24) to 5.1 ± 5.3 (range, 0-21) after March 17, 2020. VTM was not available before March 17, 2020, but was quickly adopted: asthma VTM encounters averaged 23.0 ± 19.9 per day (range, 0-70) and accounted for 61% of all encounters after March 17, 2020.Figure 1Asthma encounters before and after public health interventions were enacted. (**A**) Daily asthma encounters from January 17 to May 17, 2020. Outpatient (primary + specialty care), telephone calls (telephone), hospital (ED + inpatient), and video (primary + specialty care) encounters are shown. Five-year historical averages (March 18 to May 17, 2015-2019) with 1 SD from the mean for outpatient (light green) or hospital (light purple) encounters shown. March 17 (black-dotted line) is the date Philadelphia prohibited the operation of nonessential businesses (effective 5 PM), and the date the first COVID-19 case was diagnosed at CHOP. (**B**) Historical and 2020 asthma encounters as a percentage of total. NA, Not applicable/available.

Demographic differences in asthma health care utilization and adoption of VTM {#sec3.2}
-----------------------------------------------------------------------------

Per-patient demographic characteristics of our study population are presented in [Table I](#tbl1){ref-type="table"} . Although the total number of asthma encounters decreased after March 17, 2020, black patients represented a higher proportion of outpatient, hospital, or telephone care after this date compared with the preceding 60-day time period (54% vs 35%, 78% vs 65%, and 49% vs 24%, respectively). Patients with Medicaid coverage represented a higher proportion of outpatient or hospital care after March 17 compared with the pre--March 17, 2020 time period (55% vs 41% and 73% vs 63%, respectively). Of patients who engaged in VTM encounters in the post--March 17, 2020, time period, 26% were black and 30% had Medicaid coverage.Table IDemographic characteristics of subjects with asthma by time period and encounter typeCharacteristicCohort (n)2015-2019January 17-March 17, 2020 (5,190)March 18-May 17, 2020 (2,273)All (23,146)OutpatientHospitalTelephoneVideoAllOutpatientHospitalTelephoneVideoAllSex, n (%) Male13,644 (59)2,275 (59)826 (58)155 (62)0 (0)3,035 (58)253 (56)122 (50)169 (57)808 (59)1,294 (57) Female9,502 (41)1,608 (41)603 (42)97 (38)0 (0)2,155 (42)196 (44)124 (50)129 (43)573 (41)979 (43)Race, n (%) White9,536 (41)1,711 (44)251 (18)151 (60)0 (0)2,007 (39)131 (29)31 (13)103 (35)747 (54)979 (43) Black9,678 (42)1,366 (35)927 (65)60 (24)0 (0)2,139 (41)242 (54)191 (78)145 (49)356 (26)880 (39) Asian/Pacific Islander731 (3)168 (4)45 (3)6 (2)0 (0)204 (4)10 (2)3 (1)8 (3)37 (3)57 (3) Other3,109 (13)606 (16)203 (14)34 (13)0 (0)805 (16)64 (14)21 (9)42 (14)234 (17)348 (15) Unknown92 (0)32 (1)3 (0)1 (0)0 (0)35 (1)2 (0)0 (0)0 (0)7 (1)9 (0)Ethnicity, n (%) Non-Hispanic/Latino20,997 (91)3,426 (88)1,274 (89)223 (88)0 (0)4,579 (88)398 (89)228 (93)268 (90)1,217 (88)2,018 (89) Hispanic/Latino1,974 (9)419 (11)152 (11)27 (11)0 (0)568 (11)50 (11)18 (7)27 (9)149 (11)237 (10) Unknown175 (1)38 (1)3 (0)2 (1)0 (0)43 (1)1 (0)0 (0)3 (1)15 (1)18 (1)Birth year, n (%) Before 20001,333 (6)22 (1)1 (0)3 (1)0 (0)26 (1)9 (2)0 (0)4 (1)8 (1)20 (1) 2000-20044,096 (18)414 (11)124 (9)45 (18)0 (0)554 (11)68 (15)35 (14)64 (21)144 (10)295 (13) 2005-20096,973 (30)979 (25)268 (19)57 (23)0 (0)1,231 (24)130 (29)52 (21)62 (21)312 (23)532 (23) 2010-20148,057 (35)1,343 (35)492 (34)89 (35)0 (0)1,784 (34)141 (31)82 (33)91 (31)473 (34)753 (33) 2015 or later2,687 (12)1,125 (29)544 (38)58 (23)0 (0)1,595 (31)101 (22)77 (31)77 (26)444 (32)673 (30)Payer type, n (%) Non-Medicaid13,676 (59)2,283 (59)532 (37)222 (88)0 (0)2,863 (55)201 (45)66 (27)254 (85)969 (70)1,446 (64) Medicaid9,470 (41)1,600 (41)897 (63)30 (12)0 (0)2,327 (45)248 (55)180 (73)44 (15)412 (30)827 (36)

Decreased prescriptions of systemic steroids after COVID-19 public health interventions {#sec3.3}
---------------------------------------------------------------------------------------

Comparison of pre--and post--March 17, 2020 CHOP prescription patterns found that the relative proportions of most outpatient asthma-related prescriptions were similar before and after introduction of COVID-19 public health interventions ([Figure 2](#fig2){ref-type="fig"} , *A*). One exception was outpatient systemic steroid prescriptions, which were proportionally reduced compared with other asthma-related medications after the introduction of COVID-19 public health interventions ([Figure 2](#fig2){ref-type="fig"}, *A*). When limiting the comparison to patients who had at least 1 systemic steroid prescription from any primary asthma encounter (outpatient, emergency, or inpatient) between January 17 and May 17, 2020, there was a 83% decrease in systemic steroid prescriptions ([Figure 2](#fig2){ref-type="fig"}, *B*). Black patients and patients with Medicaid coverage represented the highest proportion of steroid prescription encounters between March 17 and May 17, 2020 (70% and 63%, respectively) (see [Table E2](#tblE2){ref-type="table"} in this article\'s Online Repository at [www.jaci-inpractice.org](http://www.jaci-inpractice.org){#intref0020}).Figure 2Asthma prescriptions before and after public health interventions were enacted. (**A**) Outpatient asthma-related prescriptions by medication class as a percentage of total (*AC*, anticholinergic; *β*~*2*~*A*, β~2~ agonists; *Bio*, biologic; *ICS*, inhaled corticosteroid; *ICS + LABA*, ICS with long-acting beta-agonist; *LM*, leukotriene modifier; *Rxs*, prescriptions; *SS*, systemic steroid). (**B**) Average number of systemic steroid prescriptions per patient per 30 days from any primary asthma encounter (outpatient, emergency, inpatient). Mean + SEM shown. Statistical comparison by paired Student *t* test. ∗∗∗∗*P* \< .0001.

Decreased RV infections after COVID-19 public health interventions {#sec3.4}
------------------------------------------------------------------

Given the importance of respiratory viral infections in asthma exacerbations, we sought to quantify the impact of COVID-19 public health interventions on respiratory viral testing. We focused on 4 key viruses; IFV-A, IFV-B, RSV, and RV. When examining viral data for the period 2019 to 2020, we noted variations in season onset and peak timing compared with historical trends. The IFV-A viral season had variable timing year-to-year and had neither an early nor a late season in the period 2019 to 2020 ([Figure 3](#fig3){ref-type="fig"} , *A*). The IFV-B viral season had an earlier onset and peaked earlier in the period 2019 to 2020, as compared with recent previous years ([Figure 3](#fig3){ref-type="fig"}, *B*). Both the IFV-A and IFV-B seasons were waning by March 17, 2020. The RSV and RV seasonal patterns were similar in all years considered before March 17 ([Figure 3](#fig3){ref-type="fig"}, *C* and *D*). RSV was waning by March 17, 2020 ([Figure 3](#fig3){ref-type="fig"}, *C*), whereas the 2020 RV season was near its peak on March 17, 2020 ([Figure 3](#fig3){ref-type="fig"}, *D*). Controlled interrupted time series results found some significant changes when comparing 2020 data to previous years\' data for all 3 of the 4 viruses (not for INF-A), though year-to-year variability was observed, consistent with variable timing of viral seasons (see [Figure E1](#figE1){ref-type="fig"} in this article\'s Online Repository at [www.jaci-inpractice.org](http://www.jaci-inpractice.org){#intref0025}). For example, significant differences were identified for RSV in the period before March 17 though some previous years had higher rates of positive testing than in 2020, whereas others had lower ([Figure E1](#figE1){ref-type="fig"}, *C*, and [Table II](#tbl2){ref-type="table"} ). RV was the only virus with significantly decreased levels in the post--March 17, 2020, time period as compared with the same time period during previous years, when years were compared individually or as a 2015 to 2019 historical average ([Figure E1](#figE1){ref-type="fig"}, *D*, and [Figure 3](#fig3){ref-type="fig"}, *E-G*).Figure 3Changes in viral respiratory testing during the COVID-19 pandemic. Deidentified institutional ED virology testing results for the period 2015 to 2020 were accessed. (**A-D**) Time series plots comparing historical data (2015-2019) to the current year (2020) for rates of positive IFV-A (*A*), IFV-B (*B*), RV (*C*), and RSV (*D*) testing vs total tests for each virus. (**E**) For 2020, RV testing data from January 17 to March 17 and March 18 to May 17 were compared to averaged historical data from the same dates from 2015 to 2019. (**F**) Bar plots comparing the 2 time periods (January 17 to March 17 and March 18 to May 17) from the averaged historical time period (2015-2019) vs the current year (2020). (**G**) ITS plots comparing time series in 2018, 2019, and 2015 to 2019 averaged vs 2020. For each, the historical data are plotted in a lighter color. The dashed line after week 9 (March 17) is the predicted data based on the previous results, and the uninterrupted line is the actual data from 2020 (exact data also plotted as circles). Significance testing via ANOVA (*F*) and details in [Table II](#tbl2){ref-type="table"} for [Figure 3](#fig3){ref-type="fig"}, *G*. *ITS*, Interrupted time series.Table IIITS analysis of viral testing data from CHOP before and after COVID-19 public health interventions were enactedYears comparedIFV-AIFV-BRVRSV2015 vs 20200.93 (NS)0.025[∗](#tbl2fnlowast){ref-type="table-fn"}0.0040[†](#tbl2fndagger){ref-type="table-fn"}0.016[∗](#tbl2fnlowast){ref-type="table-fn"}2016 vs 20200.52 (NS)0.0007[‡](#tbl2fnddagger){ref-type="table-fn"}0.021[∗](#tbl2fnlowast){ref-type="table-fn"}0.0008[‡](#tbl2fnddagger){ref-type="table-fn"}2017 vs 20200.59 (NS)0.014[∗](#tbl2fnlowast){ref-type="table-fn"}0.0006[‡](#tbl2fnddagger){ref-type="table-fn"}0.0290[∗](#tbl2fnlowast){ref-type="table-fn"}2018 vs 20200.89 (NS)0.037[∗](#tbl2fnlowast){ref-type="table-fn"}0.0035[†](#tbl2fndagger){ref-type="table-fn"}0.023[∗](#tbl2fnlowast){ref-type="table-fn"}2019 vs 20200.81 (NS)0.011[∗](#tbl2fnlowast){ref-type="table-fn"}0.011[∗](#tbl2fnlowast){ref-type="table-fn"}0.0057[†](#tbl2fndagger){ref-type="table-fn"}2015-2019 vs 20200.79 (NS)2.5 × 10^−06^[‡](#tbl2fnddagger){ref-type="table-fn"}0.0074[†](#tbl2fndagger){ref-type="table-fn"}0.14 (NS)[^3][^4][^5][^6]

Levels of 4 criteria air pollutants in Philadelphia did not significantly change during the COVID-19 pandemic compared with historical data {#sec3.5}
-------------------------------------------------------------------------------------------------------------------------------------------

Comparison of pre--and post--March 17, 2020 pollution levels ([Table III](#tbl3){ref-type="table"} ; [Figure 4](#fig4){ref-type="fig"} , *A*) found that the daily average of PM~2.5~, PM~10~, and NO~2~ levels decreased by 29.0% (2.17 μg/m^3^), 18.2% (3.13 μg/m^3^), and 44.1% (6.75 ppb), respectively, whereas ozone levels increased by 43.4% (10.08 ppb). Historical data for the period 2015 to 2019 showed comparable changes pre--and post--Mar 17: AirNow estimates found that PM~2.5~ levels decreased by 34.2% (3.88 μg/m^3^) and ozone increased by 52.4% (10.9 ppb); AirData estimates found that PM~2.5~ levels decreased by 29.2% (3.15 μg/m^3^), PM~10~ by 11.6% (2.63 μg/m^3^), and NO~2~ by 28.5% (5.49 ppb), whereas ozone increased by 46.4% (10.69 ppb). Although some of these changes differed significantly across the full range of days (January 17 to May 17), year, and/or before and after the March 17 date, none of the changes were statistically significant compared with historical trends observed across the pre--and post--March 17 60-day time period (see [Table E3](#tblE3){ref-type="table"} in this article\'s Online Repository at [www.jaci-inpractice.org](http://www.jaci-inpractice.org){#intref0030}). Specifically, PM~2.5~ and PM~10~ had significantly decreased levels in 2020 compared with previous years during the days January 17 to May 17; PM~2.5~ significantly decreased after March 17 in all years whether using AirNow or AirData historical data (*P* \< .05); ozone had significantly higher levels after March 17 and across all days whether using AirNow or AirData historical data (*P* \< .001); and NO~2~ significantly decreased across days (*P* \< .05) with no change before or after March 17 or by year. [Figure 4](#fig4){ref-type="fig"}, *B*, shows the raster of PM~2.5~ levels in Philadelphia for the 60-day pre--and post--March 17 periods along with the location of air monitoring stations that recorded PM~2.5~ measures.Table IIIMean measures of 4 criteria air pollutants in Philadelphia before and after COVID-19 public health interventions were enactedAir pollutantAirData (2015-2019)AirNow (2015-2019)AirNow (2020)January 17 to March 17March 18 to May 17January 17 to March 17March 18 to May 17January 17 to March 17March 18 to May 17NO~2~ (ppb)19.2 ± 6.813.7 ± 4.6NANA15.2 ± 7.68.5 ± 3.8Ozone (ppb)23.0 ± 6.533.7 ± 4.920.8 ± 5.831.7 ± 3.623.2 ± 8.533.2 ± 5.2PM~2.5~ (μg/m^3^)10.7 ± 3.57.6 ± 2.511.3 ± 2.47.4 ± 1.77.3 ± 4.35.2 ± 2.2PM~10~ (μg/m^3^)22.7 ± 3.420.1 ± 3.0NANA17.2 ± 7.714.0 ± 4.7[^7][^8]Figure 4Levels of 4 criteria air pollutants in Philadelphia before and after COVID-19 public health interventions were enacted. **(A)** Boxplots of averages of daily NO~2~, ozone, PM~10~, and PM~2.5~ measures corresponding to years 2020 and 2015 to 2019 sourced from AirData and AirNow for the 60-day time period before and after March 17, the day in 2020 when COVID-19 public health interventions were enacted in Philadelphia. None of the changes across March 17 were significantly different in the year 2020 compared with historical years. **(B)** Philadelphia raster layer maps showing daily average PM~2.5~ levels before and after the COVID-19 public health interventions were enacted for the year 2020 and the average of years 2015 to 2019 using AirNow data. The blue circles denote available air monitoring sites. *ppb*, Parts per billion.

Discussion {#sec4}
==========

We found that public health interventions designed to limit SARS-CoV-2 transmission in the Philadelphia region were associated with increased VTM and decreased overall asthma encounters, systemic steroid prescriptions, and RV positivity in our ED ([Figure 5](#fig5){ref-type="fig"} ). We previously noted an overall decrease in ED utilization at CHOP,[@bib32] a pattern consistent with that observed in other regions of the country, which included a shift away from in-person care and toward VTM-based care.[@bib33] Our observed decrease in the overall asthma disease burden is also consistent with national survey data.[@bib33] Figure 5Effects of public health interventions designed to limit viral transmission on asthma features. Public health interventions designed to limit viral transmission (masking, social distancing, school closures, etc) were associated with a restructuring of asthma care delivery including a reduction in in-person encounters and an increase in VTM-based care. Overall asthma encounters were reduced, as were systemic steroid prescriptions. Changes in RV infections, but not pollution levels, may have contributed to these trends.

After March 17, 2020, VTM became the most used asthma encounter modality at CHOP, enabling patients with asthma to access care while adhering to stay-at-home guidelines. Previous studies have demonstrated the utility of VTM to facilitate care delivery to underserved rural populations and as a viable substitute for both routine and acute in-person asthma care visits.[@bib34] ^,^ [@bib35] However, the rapid introduction of VTM across the country represents a new, and as such, understudied care model. Black children accounted for the majority of outpatient and hospital care after March 17, 2020, yet they represented only 26% of VTM encounters. We were unable to determine whether this observed difference by race in VTM care was due to patient preference, differences in access to VTM, or some other factor. Future studies should consider this issue carefully in light of well-known disparities in asthma prevalence, severity, and exacerbations by race, ethnicity, and socioeconomic status in the United States,[@bib36], [@bib37], [@bib38] as well as concern for a potential "digital divide" in telemedicine.[@bib39], [@bib40], [@bib41]

Changes in respiratory virus infection rates may have contributed to the decrease in asthma encounters we observed. Most notably, we found that cases of positive RV testing decreased after the introduction of public health interventions designed to limit viral transmission of SARS-CoV-2. This is relevant because RV is a key cause of asthma exacerbations.[@bib10] ^,^ [@bib11] The other 3 viruses examined (IFV-A, IFV-B, RSV) were waning by March 17, 2020, and as such likely did not play as active a role in asthma exacerbations that occurred after this date. However, we note that we were limited when comparing viral data trends across years because of variability in seasonal onset and peak timing. This variability led to mixed results on the impact of COVID-19 public health interventions on RSV. Overall, a clinically impactful effect of COVID-19--related public health interventions on RSV was unlikely, although the decrease in RV may have contributed to a decrease in asthma exacerbations after March 17.

Air pollution levels are known to vary according to season: PM~2.5~ and PM~10~ concentrations across the United States are relatively higher in summer and lower in winter,[@bib42] whereas ground-level ozone and NO~2~ are inversely related, with levels peaking in summer and winter, respectively.[@bib43] Our results for each of these 4 criteria air pollutants across the January 17 to May 17 time frame in Philadelphia are consistent with known seasonal trends. Although we did not observe statistically significant changes after COVID-19 public health interventions for these 4 pollutants, the dramatic reduction in vehicular traffic and some industrial activity likely reduced levels of specific pollutants not captured by EPA regulatory monitors. NO~2~ and PM~10~ comparisons were limited because they involved 2 different sources of data: AirNow and AirData. Although the same monitoring sites provided data to these publicly available resources, they differed in that AirData releases quality-assured data, whereas AirNow releases real-time measures. Hence, only AirNow contained 2020 measures, whereas only AirData contained complete historical measures. This limitation would likely not change our conclusions because comparison of PM~2.5~ and ozone measures derived from AirNow and AirData for the period 2015 to 2019 revealed that they were broadly similar. In addition, controlled interrupted time series results were similar whether AirNow or AirData historical measures were used for these 2 pollutants ([Table E2](#tblE2){ref-type="table"}). Our pollution results were also limited because they relied on measures taken at specific monitoring sites that may not have adequately captured differences experienced by individuals across the greater Philadelphia region. In addition to potentially changing levels of outdoor air pollutants, COVID-19--related public health interventions likely influenced pollution exposure profiles of children in other ways, including via decreased commuting and outdoor activity.

An additional factor that may have contributed to the reduced asthma disease burden and health care utilization after COVID-19 public health interventions were introduced is increased implementation of preventative measures. For example, some providers may have purposefully reached out to patients\' families to encourage filling controller medication prescriptions as the COVID-19 pandemic began, given initial concern that those with asthma had increased susceptibility to more severe outcomes with SARS-CoV-2 infection. In addition, fear of contracting COVID-19 may have reduced the likelihood of an individual accessing in-person care, as well as increased adherence to controller medications.[@bib44] Finally, just as social distancing and increased time spent indoors may have limited patient exposure to viruses and outdoor pollution, these measures may have also decreased exposure to outdoor environmental allergens that are known triggers of pediatric asthma.[@bib45] School closures may have additionally resulted in reduced exposure to allergens because school environments can be sources of allergens that increase asthma morbidity.[@bib46] ^,^ [@bib47]

Our study is subject to additional limitations worth noting. The demographic, health care utilization, and viral testing data were derived from a single institution and collected as part of routine care. Therefore, our results may not generalize to other regions and are observational in nature. We relied on primary *International Classification of Diseases* codes to identify asthma encounters, which may be affected by billing or administrative constraints, and hence may have introduced bias in our data collection. Our prescription data are incomplete in that patients may have sought care outside of our network, and it is limited in that we do not have information on prescriptions filled or adherence. Furthermore, we observed an increase in steroid prescriptions in 2020 as compared with previous years. This increase could be due to shifts in patient acuity, or provider prescription practices. Finally, use of electronic health record--derived data is subject to bias and error more broadly, which we were unable to control for, although most errors in the data would have biased us toward not observing significant changes. As such, future studies are warranted to refine our findings and improve our understanding of the effects of the COVID-19 pandemic on asthma care, triggers, and clinical outcomes.

 {#appsec1}

Figure E1Effects of public health interventions designed to limit viral transmission on viral testing. Deidentified institutional ED virology testing results for the period 2015 to 2020 were accessed. (**A-D**) Bar plots of rates of positive viral testing (IFV-A, IFV-B, RSV, and RV, respectively) from January 17 to March 17 vs March 18 to May 17 in the period 2015 to 2019 (and the average of that range) vs 2020.Table E1Asthma medication classesMedicine ID no.NameClass61180Decadron IJSystemic steroid61181Decadron IVSystemic steroid61183Decadron ORSystemic steroid132559DEX Combo 8-4 mg/mL IJ SUSPSystemic steroid132710DEX Combo IJSystemic steroid132560DEX LA 16 16 mg/mL IJ SUSPSystemic steroid132711DEX LA 16 IJSystemic steroid132561DEX LA 8 8 mg/mL IJ SUSPSystemic steroid132712DEX LA 8 IJSystemic steroid130359Dexameth SOD PHOS-BUPIV-LIDOSystemic steroid90302Dexamethasone (glucocorticosteroids)Systemic steroid61547Dexamethasone (PAK) ORSystemic steroid200200162Dexamethasone 0.1 mg/mL (D5W) injection customSystemic steroid200200163Dexamethasone 0.1 mg/mL (NSS) injection customSystemic steroid2762Dexamethasone 0.5 mg OR TABSSystemic steroid200200499Dexamethasone 0.5 mg OR TABS (CHEMO)Systemic steroid2759Dexamethasone 0.5 mg/5 mL OR ELIXSystemic steroid2760Dexamethasone 0.5 mg/5 mL OR SOLNSystemic steroid2763Dexamethasone 0.75 mg OR TABSSystemic steroid2764Dexamethasone 1 mg OR TABSSystemic steroid200201009Dexamethasone 1 mg OR TABS (CHEMO)Systemic steroid200200164Dexamethasone 1 mg/mL (D5W) injection customSystemic steroid200200874Dexamethasone 1 mg/mL (NSS) injection customSystemic steroid21292Dexamethasone 1 mg/mL OR CONCSystemic steroid200200501Dexamethasone 1 mg/mL OR CONC (CHEMO)Systemic steroid135377Dexamethasone 1.5 mg (21) OR TBPKSystemic steroid135378Dexamethasone 1.5 mg (35) OR TBPKSystemic steroid135379Dexamethasone 1.5 mg (51) OR TBPKSystemic steroid2765Dexamethasone 1.5 mg OR TABSSystemic steroid200200502Dexamethasone 1.5 mg OR TABS (CHEMO)Systemic steroid2766Dexamethasone 2 mg OR TABSSystemic steroid200201008Dexamethasone 2 mg OR TABS (CHEMO)Systemic steroid2767Dexamethasone 4 mg OR TABSSystemic steroid200200503Dexamethasone 4 mg OR TABS (CHEMO)Systemic steroid200200504Dexamethasone 4 mg/mL (undiluted) injection (CHEMO) customSystemic steroid200200165Dexamethasone 4 mg/mL (undiluted) injection customSystemic steroid2768Dexamethasone 6 mg OR TABSSystemic steroid200200505Dexamethasone 6 mg OR TABS (CHEMO)Systemic steroid132777Dexamethasone ACE & SOD PHOSSystemic steroid132551Dexamethasone ACE & SOD PHOS 8-4 mg/mL IJ SUSPSystemic steroid132713Dexamethasone ACE & SOD PHOS IJSystemic steroid90303Dexamethasone acetateSystemic steroid29197Dexamethasone acetate 16 mg/mL IJ SUSPSystemic steroid2769Dexamethasone acetate 8 mg/mL IJ SUSPSystemic steroid61549Dexamethasone acetate IJSystemic steroid2770Dexamethasone acetate POWDSystemic steroid27267Dexamethasone base POWDSystemic steroid200200166Dexamethasone injection custom orderableSystemic steroid200200506Dexamethasone injection custom orderable (CHEMO)Systemic steroid2758Dexamethasone Intensol 1 mg/mL OR CONCSystemic steroid61551Dexamethasone Intensol ORSystemic steroid61554Dexamethasone ORSystemic steroid18270Dexamethasone POWDSystemic steroid130355Dexamethasone SOD PHOS & BUPIVSystemic steroid130356Dexamethasone SOD PHOS-LIDOSystemic steroid121371Dexamethasone SOD Phosphate PF 10 mg/mL IJ SOLNSystemic steroid121730Dexamethasone SOD Phosphate PF IJSystemic steroid200201236Dexamethasone sodium phosphate (CHEMO) 4 mg/mL IJ SOLNSystemic steroid90304Dexamethasone sodium phosphate (glucocorticosteroids)Systemic steroid2771Dexamethasone sodium phosphate 10 mg/mL IJ SOLNSystemic steroid200201160Dexamethasone sodium phosphate 10 mg/mL IJ SOLN (CHEMO)Systemic steroid128185Dexamethasone sodium phosphate 100 mg/10 mL IJ SOLNSystemic steroid128184Dexamethasone sodium phosphate 120 mg/30 mL IJ SOLNSystemic steroid128183Dexamethasone sodium phosphate 20 mg/5 mL IJ SOLNSystemic steroid2772Dexamethasone sodium phosphate 4 mg/mL IJ SOLNSystemic steroid200201065Dexamethasone sodium phosphate 4 mg/mL INH SOLN customSystemic steroid61557Dexamethasone sodium phosphate IJSystemic steroid61558Dexamethasone sodium phosphate IVSystemic steroid2776Dexamethasone sodium phosphate POWDSystemic steroid135753DEXPAK 10 DAY 1.5 mg (35) OR TBPKSystemic steroid97925DEXPAK 10 DAY ORSystemic steroid135749DEXPAK 13 DAY 1.5 mg (51) OR TBPKSystemic steroid61586DEXPAK 13 DAY ORSystemic steroid135755DEXPAK 6 DAY 1.5 mg (21) OR TBPKSystemic steroid100127DEXPAK 6 DAY ORSystemic steroid130145Doubledex 10 mg/mL IJ KITSystemic steroid130264Doubledex IJSystemic steroid70802Medrol (PAK) ORSystemic steroid17892Medrol 16 mg OR TABSSystemic steroid5790Medrol 2 mg OR TABSSystemic steroid5792Medrol 32 mg OR TABSSystemic steroid17891Medrol 4 mg OR TABSSystemic steroid135742Medrol 4 mg OR TBPKSystemic steroid5793Medrol 8 mg OR TABSSystemic steroid70803Medrol ORSystemic steroid71141Methylpred 40 IJSystemic steroid130360Methylprednisol & BUPIV & LIDOSystemic steroid90309MethylprednisoloneSystemic steroid128079Methylprednisolone & lidocaine IJSystemic steroid200200507Methylprednisolone (CHEMO) injection custom orderableSystemic steroid71143Methylprednisolone (PAK) ORSystemic steroid5957Methylprednisolone 16 mg OR TABSSystemic steroid12408Methylprednisolone 2 mg OR TABSSystemic steroid12410Methylprednisolone 32 mg OR TABSSystemic steroid5958Methylprednisolone 4 mg OR TABSSystemic steroid135372Methylprednisolone 4 mg OR TBPKSystemic steroid12411Methylprednisolone 8 mg OR TABSSystemic steroid128116Methylprednisolone ACE-LIDOSystemic steroid132562Methylprednisolone ACE-LIDO 40-10 mg/mL IJ SUSPSystemic steroid132542Methylprednisolone ACE-LIDO 80-10 mg/mL IJ SUSPSystemic steroid132732Methylprednisolone ACE-LIDO IJSystemic steroid90310Methylprednisolone acetateSystemic steroid132539Methylprednisolone acetate 100 mg/mL IJ SUSPSystemic steroid5959Methylprednisolone acetate 20 mg/mL IJ SUSPSystemic steroid5959Methylprednisolone acetate 40 mg/mL IJ SUSPSystemic steroid200201903Methylprednisolone acetate 40 mg/mL IJ SUSP (IR use only) CSystemic steroid5961Methylprednisolone acetate 80 mg/mL IJ SUSPSystemic steroid71145Methylprednisolone acetate IJSystemic steroid121372Methylprednisolone acetate PF 40 mg/mL IJ SUSPSystemic steroid121373Methylprednisolone acetate PF 80 mg/mL IJ SUSPSystemic steroid121778Methylprednisolone acetate PF IJSystemic steroid20399Methylprednisolone acetate POWDSystemic steroid200200293Methylprednisolone injection custom orderableSystemic steroid71147Methylprednisolone ORSystemic steroid20398Methylprednisolone POWDSystemic steroid200200508Methylprednisolone sodium Succ (CHEMO) 1 mg/mL (NSS) INJECTSystemic steroid200200509Methylprednisolone sodium Succ (CHEMO) 1000 mg IJ SOLRSystemic steroid200200510Methylprednisolone sodium Succ (CHEMO) 125 mg IJ SOLRSystemic steroid200201004Methylprednisolone sodium Succ (CHEMO) 125 mg/mL (SWFI) INJSystemic steroid200200511Methylprednisolone sodium Succ (CHEMO) 40 mg IJ SOLRSystemic steroid200201002Methylprednisolone sodium Succ (CHEMO) 40 mg/mL (SWFI) INJSystemic steroid90311Methylprednisolone sodium Succ (glucocorticosteroids)Systemic steroid52078Methylprednisolone sodium Succ 1 g IJ SOLRSystemic steroid200200294Methylprednisolone sodium Succ 1 mg/mL (NSS) Injection CUSTSystemic steroid12412Methylprednisolone sodium Succ 1000 mg IJ SOLRSystemic steroid12413Methylprednisolone sodium Succ 125 mg IJ SOLRSystemic steroid200201001Methylprednisolone sodium Succ 125 mg/mL (SWFI) Injection CSystemic steroid12414Methylprednisolone sodium Succ 2000 mg IJ SOLRSystemic steroid12415Methylprednisolone sodium Succ 40 mg IJ SOLRSystemic steroid200200999Methylprednisolone sodium SUCC 40 mg/mL (SWFI) injection CUSystemic steroid12416Methylprednisolone sodium Succ 500 mg IJ SOLRSystemic steroid71149Methylprednisolone sodium Succ IJSystemic steroid89026Millipred 10 mg/5 mL OR SOLNSystemic steroid97492Millipred 5 mg OR TABSSystemic steroid135762Millipred DP 12-DAY 5 mg (48) OR TBPKSystemic steroid111603Millipred DP 12-DAY ORSystemic steroid135756Millipred DP 5 MG (21) OR TBPKSystemic steroid135757Millipred DP 5 mg (48) OR TBPKSystemic steroid100265Millipred DP ORSystemic steroid89183Millipred ORSystemic steroid33929Orapred 15 mg/5 mL OR SOLNSystemic steroid51263Orapred ODT 10 mg OR TBDPSystemic steroid50493Orapred ODT 15 mg OR TBDPSystemic steroid51264Orapred ODT 30 mg OR TBDPSystemic steroid73649Orapred ODT ORSystemic steroid73650ORAPRED ORSystemic steroid97196Pediapred 6.7 (5 mg prednisolone base) mg/5 mL OR SOLNSystemic steroid74412Pediapred ORSystemic steroid90312PrednisoloneSystemic steroid100776Prednisolone 15 mg/5 mL OR SOLNSystemic steroid13018Prednisolone 15 mg/5 mL OR SYRPSystemic steroid135373Prednisolone 5 mg (21) OR TBPKSystemic steroid135374Prednisolone 5 mg (48) OR TBPKSystemic steroid7711Prednisolone 5 mg OR TABSSystemic steroid90313Prednisolone acetate (glucocorticosteroids)Systemic steroid108953Prednisolone acetate 16.7 (15 mg base) mg/5 mL OR SUSPSystemic steroid75589Prednisolone acetate IJSystemic steroid109427Prednisolone acetate ORSystemic steroid7716Prednisolone acetate POWDSystemic steroid20923Prednisolone anhydrous POWDSystemic steroid75593Prednisolone ORSystemic steroid7712Prednisolone POWDSystemic steroid75595Prednisolone SOD phosphate ORSystemic steroid90314Prednisolone sodium phosphate (glucocorticosteroids)Systemic steroid51252Prednisolone sodium phosphate 10 mg OR TBDPSystemic steroid89025Prednisolone sodium phosphate 10 mg/5 mL OR SOLNSystemic steroid50481Prednisolone sodium phosphate 15 mg OR TBDPSystemic steroid200201856Prednisolone sodium phosphate 15 mg/5 mL (SWISH & SPIT) OR SSystemic steroid33930Prednisolone sodium phosphate 15 mg/5 mL OR SOLNSystemic steroid200200533Prednisolone sodium phosphate 15 mg/5 mL OR SOLN (CHEMO) CusSystemic steroid97477Prednisolone sodium phosphate 20 mg/5 mL OR SOLNSystemic steroid121526Prednisolone sodium phosphate 25 mg/5 mL OR SOLNSystemic steroid51253Prednisolone sodium phosphate 30 mg OR TBDPSystemic steroid96082Prednisolone sodium phosphate 6.7 (5 mg base) mg/5 mL OR SOLNSystemic steroid75598Prednisolone sodium phosphate ORSystemic steroid20439Prednisolone sodium phosphate POWDSystemic steroid90315PrednisoneSystemic steroid75601Prednisone (PAK) ORSystemic steroid200200351Prednisone 0.5 mg/mL OR SOL customSystemic steroid7721Prednisone 1 mg OR TABSSystemic steroid200200492Prednisone 1 mg OR TABS (CHEMO) customSystemic steroid120527Prednisone 1 mg OR TBECSystemic steroid135431Prednisone 10 mg (21) OR TBPKSystemic steroid135432Prednisone 10 mg (48) OR TBPKSystemic steroid7722Prednisone 10 mg OR TABSSystemic steroid200200493Prednisone 10 mg OR TABS (CHEMO) customSystemic steroid120528Prednisone 2 mg OR TBECSystemic steroid7723Prednisone 2.5 mg OR TABSSystemic steroid200200494Prednisone 2.5 mg OR TABS (CHEMO) customSystemic steroid7724Prednisone 20 mg OR TABSSystemic steroid200200495Prednisone 20 mg OR TABS (CHEMO) customSystemic steroid135375Prednisone 5 mg (21) OR TBPKSystemic steroid135376Prednisone 5 mg (48) OR TBPKSystemic steroid7725Prednisone 5 mg OR TABSSystemic steroid200200496Prednisone 5 mg OR TABS (CHEMO) customSystemic steroid120529Prednisone 5 mg OR TBECSystemic steroid7720Prednisone 5 mg/5 mL OR SOLNSystemic steroid7718Prednisone 5 mg/mL OR CONCSystemic steroid7726Prednisone 50 mg OR TABSSystemic steroid22674Prednisone intensol 5 mg/mL OR CONCSystemic steroid75602Prednisone Intensol ORSystemic steroid75603Prednisone ORSystemic steroid7727Prednisone POWDSystemic steroid7732Prelone 15 mg/5 mL OR SYRPSystemic steroid75620Prelone ORSystemic steroid8767Solu-Medrol 1000 mg IJ SOLRSystemic steroid8768Solu-Medrol 125 mg IJ SOLRSystemic steroid8769Solu-Medrol 2 g IJ SOLRSystemic steroid8770Solu-Medrol 40 mg IJ SOLRSystemic steroid8771Solu-Medrol 500 mg IJ SOLRSystemic steroid79793Solu-Medrol IJSystemic steroid79797Solurex IJSystemic steroid79798Solurex LA IJSystemic steroid80064Sterapred 12 DAY ORSystemic steroid80065Sterapred DS 12 DAY ORSystemic steroid80066Sterapred DS ORSystemic steroid80067Sterapred ORSystemic steroid36549Accuneb 0.63 mg/3 mL IN NEBUBeta-agonist36550Accuneb 1.25 mg/3 mL IN NEBUBeta-agonist53821Accuneb INBeta-agonist54377Airet INBeta-agonist91225AlbuterolBeta-agonist54543Albuterol INBeta-agonist20261Albuterol POWDBeta-agonist91226Albuterol sulfateBeta-agonist311Albuterol sulfate (2.5 mg/3 mL) 0.083% IN NEBUBeta-agonist312Albuterol sulfate (5 mg/mL) 0.5% IN NEBUBeta-agonist200200745Albuterol sulfate (5 mg/mL) 0.5% NEB continuous customBeta-agonist36541Albuterol sulfate 0.63 mg/3 mL IN NEBUBeta-agonist36542Albuterol sulfate 1.25 mg/3 mL IN NEBUBeta-agonist132129Albuterol sulfate 108 (90 μg base) μg/ACT IN AEPBBeta-agonist315Albuterol sulfate 2 mg OR TABSBeta-agonist314Albuterol sulfate 2 mg/5 mL OR SYRPBeta-agonist316Albuterol sulfate 4 mg OR TABSBeta-agonist39219Albuterol sulfate ER 4 mg OR TB12Beta-agonist39220Albuterol sulfate ER 8 mg OR TB12Beta-agonist123418Albuterol sulfate ER ORBeta-agonist21155Albuterol sulfate HFA 108 (90 μg base) μg/ACT IN AERSBeta-agonist200200995Albuterol sulfate HFA 108 (90 μg base) μg/ACT IN AERS (ED HOM)Beta-agonist200200994Albuterol sulfate HFA 108 (90 μg base) μg/ACT IN AERS (OR Use)Beta-agonist98773Albuterol sulfate HFA INBeta-agonist54545Albuterol sulfate INBeta-agonist54546Albuterol sulfate ORBeta-agonist317Albuterol sulfate POWDBeta-agonist2002001992Albuterol sulfate variable dose for PyxisBeta-agonist91234Levalbuterol HCL (sympathomimetics)Beta-agonist37337Levalbuterol HCL 0.31 mg/3 mL IN NEBUBeta-agonist29159Levalbuterol HCL 0.63 mg/3 mL IN NEBUBeta-agonist44604Levalbuterol HCL 1.25 mg/0.5 mL IN NEBUBeta-agonist29160Levalbuterol HCL 1.25 mg/3 mL IN NEBUBeta-agonist69516Levalbuterol HCL INBeta-agonist91235Levalbuterol tartrateBeta-agonist49020Levalbuterol tartrate 45 μg/ACT IN AEROBeta-agonist69517Levalbuterol tartrate INBeta-agonist50377Proair HFA 108 (90 μg base) μg/ACT IN AERSBeta-agonist75956Proair HFA INBeta-agonist132126Proair respiclick 108 (90 μg base) μg/ACT IN AEPBBeta-agonist132374Proair respiclick INBeta-agonist21277Proventil HFA 108 (90 μg base) μg/ACT IN AERSBeta-agonist76250Proventil HFA INBeta-agonist76251Proventil INBeta-agonist76252Proventil ORBeta-agonist200200406Terbutaline 0.1% nebulization SOLN customBeta-agonist91239Terbutaline sulfateBeta-agonist200200937Terbutaline sulfate 0.1 mg/mL IJ SOLN customBeta-agonist13430Terbutaline sulfate 1 mg/mL IJ SOLNBeta-agonist200201165Terbutaline sulfate 1 mg/mL IJ SOLN (subcutaneous use only)Beta-agonist200200407Terbutaline sulfate 1 mg/mL SUSP customBeta-agonist13432Terbutaline sulfate 2.5 mg OR TABSBeta-agonist13433Terbutaline sulfate 5 mg OR TABSBeta-agonist81143Terbutaline sulfate IJBeta-agonist200200938Terbutaline sulfate injection custom orderableBeta-agonist81144Terbutaline sulfate ORBeta-agonist20433Terbutaline sulfate POWDBeta-agonist37396Xopenex 0.31 mg/3 mL IN NEBUBeta-agonist29270Xopenex 0.63 mg/3 mL IN NEBUBeta-agonist29271Xopenex 1.25 mg/3 mL IN NEBUBeta-agonist44598Xopenex concentrate 1.25 mg/0.5 mL IN NEBUBeta-agonist83997Xopenex concentrate INBeta-agonist49017Xopenex HFA 45 μg/ACT IN AEROBeta-agonist83998Xopenex HFA INBeta-agonist83999Xopenex INBeta-agonist54262Aerobid INICS54263Aerobid-M INICS127561Aerospan 80 μg/ACT IN AERSICS127718Aerospan INICS96592Alvesco 160 μg/ACT IN AERSICS96591Alvesco 80 μg/ACT IN AERSICS97729Alvesco INICS130919Arnuity Ellipta 100 μg/ACT IN AEPBICS130920Arnuity Ellipta 200 μg/ACT IN AEPBICS130972Arnuity Ellipta INICS47449Asmanex 120 metered doses 220 μg/INH IN AEPBICS55726Asmanex 120 metered doses INICS47450Asmanex 14 metered doses 220 μg/INH IN AEPBICS55727Asmanex 14 metered doses INICS89591Asmanex 30 metered doses 110 μg/INH IN AEPBICS47447Asmanex 30 metered doses 220 μg/INH IN AEPBICS55728Asmanex 30 metered doses INICS47448Asmanex 60 metered doses 220 μg/INH IN AEPBICS55729Asmanex 60 metered doses INICS111284Asmanex 7 metered doses 110 μg/INH IN AEPBICS111529Asmanex 7 metered doses INICS130881Asmanex HFA 100 μg/ACT IN AEROICS130893Asmanex HFA 200 μg/ACT IN AEROICS130973Asmanex HFA INICS56112Azmacort INICS91254Beclomethasone dipropionate (steroid inhalants)ICS33588Beclomethasone dipropionate 40 μg/ACT IN AERSICS33589Beclomethasone dipropionate 80 μg/ACT IN AERSICS56626Beclomethasone dipropionate INICS56627Beclovent INICS91255Budesonide (steroid inhalants)ICS33341Budesonide 0.25 mg/2 mL IN SUSPICS33342Budesonide 0.5 mg/2 mL IN SUSPICS200201034Budesonide 0.5 mg/2 mL NEB for *po* useICS85108Budesonide 1 mg/2 mL IN SUSPICS98957Budesonide 180 μg/ACT IN AEPBICS98956Budesonide 90 μg/ACT IN AEPBICS98788Budesonide INICS98448Ciclesonide (steroid inhalants)ICS96103Ciclesonide 160 μg/ACT IN AERSICS96102Ciclesonide 80 μg/ACT IN AERSICS97832Ciclesonide INICS98924Flovent Diskus 100 μg/BLIST IN AEPBICS98925Flovent Diskus 250 μg/BLIST IN AEPBICS53294Flovent Diskus 50 μg/BLIST IN AEPBICS64815Flovent Diskus INICS46255Flovent HFA 110 μg/ACT IN AEROICS46256Flovent HFA 220 μg/ACT IN AEROICS46254Flovent HFA 44 μg/ACT IN AEROICS64816Flovent HFA INICS64817Flovent INICS64818Flovent Rotadisk INICS91256Flunisolide (steroid inhalants)ICS127699Flunisolide HFAICS127438Flunisolide HFA 80 μg/ACT IN AERSICS127758Flunisolide HFA INICS64856Flunisolide INICS20361Flunisolide POWDICS131120Fluticasone furoate (steroid inhalants)ICS130716Fluticasone furoate 100 μg/ACT IN AEPBICS130717Fluticasone furoate 200 μg/ACT IN AEPBICS131018Fluticasone furoate INICS91257Fluticasone propionate (INHAL)ICS32750Fluticasone propionate (INHAL) 100 μg/BLIST IN AEPBICS32751Fluticasone propionate (INHAL) 250 μg/BLIST IN AEPBICS32749Fluticasone propionate (INHAL) 50 μg/BLIST IN AEPBICS64934Fluticasone propionate (INHAL) INICS91258Fluticasone propionate HFAICS46046Fluticasone propionate HFA 110 μg/ACT IN AEROICS46047Fluticasone propionate HFA 220 μg/ACT IN AEROICS46045Fluticasone propionate HFA 44 μg/ACT IN AEROICS134419Fluticasone propionate HFA INICS91259Mometasone furoate (steroid inhalants)ICS130882Mometasone furoate 100 μg/ACT IN AEROICS89590Mometasone furoate 110 μg/INH IN AEPBICS130883Mometasone furoate 200 μg/ACT IN AEROICS47345Mometasone furoate 220 μg/INH IN AEPBICS71565Mometasone furoate INICS33535Pulmicort 0.25 mg/2 mL IN SUSPICS33536Pulmicort 0.5 mg/2 mL IN SUSPICS85111Pulmicort 1 mg/2 mL IN SUSPICS99899Pulmicort flexhaler 180 μg/ACT IN AEPBICS99900Pulmicort flexhaler 90 μg/ACT IN AEPBICS76405Pulmicort flexhaler INICS76406Pulmicort INICS76407Pulmicort turbuhaler INICS33585QVAR 40 μg/ACT IN AERSICS33586QVAR 80 μg/ACT IN AERSICS76802QVAR INICS91260Triamcinolone acetonide (steroid inhalants)ICS85453Triamcinolone acetonide INICS83089Vanceril double strength INICS83090Vanceril INICS105585Advair Diskus 100-50 μg/dose IN AEPBICS + LABA105588Advair Diskus 250-50 μg/dose IN AEPBICS + LABA105589Advair Diskus 500-50 μg/dose IN AEPBICS + LABA54204Advair Diskus INICS + LABA50623Advair HFA 115-21 μg/ACT IN AEROICS + LABA50624Advair HFA 230-21 μg/ACT IN AEROICS + LABA50622Advair HFA 45-21 μg/ACT IN AEROICS + LABA54205Advair HFA INICS + LABA125719BREO Ellipta 100-25 μg/INH IN AEPBICS + LABA132901BREO Ellipta 200-25 μg/INH IN AEPBICS + LABA125944BREO Ellipta INICS + LABA91246Budesonide-formoterol fumarateICS + LABA53024Budesonide-formoterol fumarate 160-4.5 μg/ACT IN AEROICS + LABA53023Budesonide-formoterol fumarate 80-4.5 μg/ACT IN AEROICS + LABA57629Budesonide-formoterol fumarate INICS + LABA110610Dulera 100-5 μg/ACT IN AEROICS + LABA110611Dulera 200-5 μg/ACT IN AEROICS + LABA110811Dulera INICS + LABA126085Fluticasone furoate-VilanterolICS + LABA125641Fluticasone furoate-Vilanterol 100-25 μg/INH IN AEPBICS + LABA132806Fluticasone furoate-Vilanterol 200-25 μg/INH IN AEPBICS + LABA125999Fluticasone furoate-Vilanterol INICS + LABA91247Fluticasone-salmeterolICS + LABA105249Fluticasone-salmeterol 100-50 μg/dose IN AEPBICS + LABA50619Fluticasone-salmeterol 115-21 μg/ACT IN AEROICS + LABA50620Fluticasone-salmeterol 230-21 μg/ACT IN AEROICS + LABA105250Fluticasone-salmeterol 250-50 μg/dose IN AEPBICS + LABA50618Fluticasone-salmeterol 45-21 μg/ACT IN AEROICS + LABA105251Fluticasone-salmeterol 500-50 μg/dose IN AEPBICS + LABA64938Fluticasone-salmeterol INICS + LABA111224Mometasone furo-formoterol FUMICS + LABA110576Mometasone furo-formoterol FUM 100-5 μg/ACT IN AEROICS + LABA110577Mometasone furo-formoterol FUM 200-5 μg/ACT IN AEROICS + LABA110835Mometasone furo-formoterol FUM INICS + LABA53239Symbicort 160-4.5 μg/ACT IN AEROICS + LABA53238Symbicort 80-4.5 μg/ACT IN AEROICS + LABA80691Symbicort INICS + LABA128121Umeclidinium-VilanterolICS + LABA127865UMeclidinium-Vilanterol 62.5-25 μg/INH IN AEPBICS + LABA128105Umeclidinium-Vilanterol INICS + LABA30756Accolate 10 mg OR TABSLeukotriene modulators21303Accolate 20 mg OR TABSLeukotriene modulators53764Accolate ORLeukotriene modulators91262Montelukast sodium (leukotriene modulators)Leukotriene modulators26447Montelukast sodium 10 mg OR TABSLeukotriene modulators31645Montelukast sodium 4 mg OR CHEWLeukotriene modulators41211Montelukast sodium 4 mg OR PKTLeukotriene modulators26448Montelukast sodium 5 mg OR ChewLeukotriene modulators71666Montelukast sodium ORLeukotriene modulators26454Singulair 10 mg OR TABSLeukotriene modulators31649Singulair 4 mg OR ChewLeukotriene modulators41210Singulair 4 mg OR PKTLeukotriene modulators26451Singulair 5 mg OR ChewLeukotriene modulators79047Singulair ORLeukotriene modulators91263ZafirlukastLeukotriene modulators30767Zafirlukast 10 mg OR TABSLeukotriene modulators21309Zafirlukast 20 mg OR TABSLeukotriene modulators84136Zafirlukast ORLeukotriene modulators91261ZileutonLeukotriene modulators22305Zileuton 600 mg OR TABSLeukotriene modulators85485Zileuton ER 600 mg OR TB12Leukotriene modulators120894Zileuton ER ORLeukotriene modulators84194Zileuton ORLeukotriene modulators22304Zyflo 600 mg OR TABSLeukotriene modulators85530Zyflo CR 600 mg OR TB12Leukotriene modulators85882Zyflo CR ORLeukotriene modulators84345Zyflo ORLeukotriene modulators134493MepolizumabBiologics134274Mepolizumab 100 mg SC SOLRBiologics134437Mepolizumab SCBiologics134298Nucala 100 mg SC SOLRBiologics134446Nucala SCBiologics91264OmalizumabBiologics41330Omalizumab 150 mg SC SOLRBiologics73347Omalizumab SCBiologics41342Xolair 150 mg SC SOLRBiologics83995Xolair SCBiologics120900Aclidinium bromideAnticholinergics120515Aclidinium bromide 400 μg/ACT IN AEPBAnticholinergics120732Aclidinium bromide INAnticholinergics46720Atrovent HFA 17 μg/ACT IN AERSAnticholinergics55931Atrovent HFA INAnticholinergics55932Atrovent INAnticholinergics134491Glycopyrrolate (bronchodilators-anticholinergics)Anticholinergics134424Glycopyrrolate INAnticholinergics130918Incruse Ellipta 62.5 μg/INH IN AEPBAnticholinergics131033Incruse Ellipta INAnticholinergics91220Ipratropium bromide (bronchodilators- anticholinergics)Anticholinergics14727Ipratropium bromide 0.02 % IN SOLNAnticholinergics91221Ipratropium bromide HFAAnticholinergics46527Ipratropium bromide HFA 17 μg/ACT IN AERSAnticholinergics68438Ipratropium bromide HFA INAnticholinergics68439Ipratropium bromide INAnticholinergics20367Ipratropium bromide POWDAnticholinergics134455Seebri Neohaler INAnticholinergics43683Spiriva Handihaler 18 μg IN CAPSAnticholinergics79945Spiriva Handihaler INAnticholinergics133764Spiriva Respimat 1.25 μg/ACT IN AERSAnticholinergics130566Spiriva Respimat 2.5 μg/ACT IN AERSAnticholinergics130663Spiriva Respimat INAnticholinergics91222Tiotropium bromide monohydrateAnticholinergics133714Tiotropium bromide monohydrate 1.25 μg/ACT IN AERSAnticholinergics43672Tiotropium bromide monohydrate 18 μg IN CAPSAnticholinergics130394Tiotropium bromide monohydrate 2.5 μg/ACT IN AERSAnticholinergics81562Tiotropium bromide monohydrate INAnticholinergics120704Tudorza Pressair 400 μg/ACT IN AEPBAnticholinergics120880Tudorza Pressair INAnticholinergics131119Umeclidinium bromideAnticholinergics130705Umeclidinium bromide 62.5 μg/INH IN AEPBAnticholinergics131098Umeclidinium bromide INAnticholinergics91245Ipratropium-albuterolAnticholinergics97202Ipratropium-albuterol 0.5-2.5 (3) mg/3 mL IN SOLNAnticholinergics16477Ipratropium-albuterol 18-103 μg/ACT IN AEROAnticholinergics119838Ipratropium-albuterol 20-100 μg/ACT IN AERSAnticholinergics98087Ipratropium-albuterol INAnticholinergics[^9]Table E2Demographic characteristics of asthma prescription encountersCharacteristicPrescription cohort (n)All medicines (1624)Steroids (402)Sex, n (%) Male917 (56)213 (53) Female708 (44)189 (47)Race, n (%) White664 (41)74 (18) Black666 (41)280 (70) Asian/Pacific Islander36 (2)6 (1) Other252 (16)42 (10) Unknown7 (0)0 (0)Ethnicity, n (%) Non-Hispanic/Latino1434 (88)372 (93) Hispanic/Latino180 (11)30 (7) Unknown11 (1)0 (0)Birth year, n (%) Before 200011 (1)1 (0) 2000-2004208 (13)62 (15) 2005-2009392 (24)85 (21) 2010-2014533 (33)131 (33) 2015 or later481 (30)123 (31)Payer type, n (%) Non-Medicaid912 (56)148 (37) Medicaid713 (44)254 (63)Table E3Controlled interrupted time series regression analysis results for 4 criteria air pollutantsVariablesPM~2.5~OzonePM~10~NO~2~AirNowAirDataAirNowAirDataAirDataAirDataDays (*P* value)−0.03 (.064)−0.05 (.002)0.26 (\<.0001)0.27 (\<.0001)−0.044 (.23)−0.07 (.04)Year 2020 (*P* value)−3.51 (.0005)−3.58 (.0002)2.18 (.25)1.16 (.54)−5.40 (.004)−0.77 (.66)Covid_restrictions (*P* value)−5.25 (.009)−4.56 (.019)16.08 (\<.0001)12.90 (.0007)−0.52 (.88)−0.33 (.92)Days × Year 2020 (*P* value)0.0009 (.97)0.02 (.41)−0.03 (.52)−0.04 (.42)−0.005 (.92)−0.01 (.70)Days × Covid_restrictions (*P* value)0.045 (.10)0.05 (.04)−0.24 (\<.0001)−0.2 (\<.0001)0.006 (.90)−0.001 (.98)Year 2020 × Covid_restrictions (*P* value)2.24 (.42)1.56 (.56)−6.56 (.21)−3.48 (.51)−7.57 (.15)−5.5 (.26)Days × Year 2020 × Covid_restrictions (*P* value)−0.005 (.88)−0.01 (.66)0.09 (.2)0.05 (.44)0.08 (.27)0.05 (.41)[^10]
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[^1]: These authors contributed equally to this work.

[^2]: These authors contributed equally to this work.

[^3]: *ITS,* Interrupted time series; *NS*, not significant.

[^4]: *P* ≤ .05.

[^5]: *P* ≤ .01.

[^6]: *P* ≤ .001.

[^7]: *NA*, Not available; *ppb*, parts per billion.

[^8]: Values are mean ± SD.

[^9]: *AERO*, Aerosolized; *AERS*, aerosolized; *CHEMO*, chemotherapy; *CONC*, concentrate; *CUST*, custom; *D5W*, dextrose 5% in water; *Dex*, dexamethasone; *ELIX*, elixer; *ER*, extended-release; *HCL*, hydrochloride; *HFA*, hydrofluoroalkane; *ICS*, inhaled corticosteroid; *IJ*, injection; *IN*, inhallation; *INH*, inhallation; *INHAL*, inhallation; *INJ*, injection; *INJECT*, injection; *IV*, intravenous; *LABA*, long-acting beta agonist; *LIDO*, lidocaine; *NEB*, nebulizer; *NEBU*, nebulizer; *NSS*, normal saline solution; *OR*, oral; *PAK*, pack; *PHOS*, phosphate; *PKT*, packet; *po*, *per os* (by mouth); *POWD*, powder; *SC*, subcutaneous; *SOD*, sodium; *SOL*, solution; *SOLN*, solution; *SUSP*, suspension; *SWFI*, sterile water for injection; *SYRP*, syrup; *TABS*, tablets; *TBEC*, enteric coated tablet; *TBPK*, tablet pack.

[^10]: Outcome was levels of each pollutant. Independent variables included days, referring to the 120 d between January 17 and May 17; year 2020, indicating whether it was the year 2020 or historical time period; covid_restrictions, indicating whether the measure was from before or after March 17. Each column corresponds to 1 model with indicated outcome variable and source of historical measures (AirNow or AirData). Terms in the model are indicated in each row. Values are coefficient estimate (*P* value).
